Genflow Completes Dosing Phase of Canine Gene Therapy Trial No Adverse Events Reported During Administration
Genflow Completes Dosing Phase of Canine Gene Therapy Trial No Adverse Events Reported During Administration
Genflow to Attend the 44th Annual J.P. Morgan Healthcare Conference
Update on Animal Health Program
Genflow Biosciences Raises £440,000 Through Alternative Share Placement.
Genflow Biosciences PLC (LON: GENF) has submitted a formal request for examination of its patent application in China relating to proprietary SIRT6 variants designed for the treatment of Non-Alcoholic Steatohepatitis
Genflow Biosciences PLC (LSE: GENF, OTCQB: GENFF) has announced progress across its two core research programmes, bringing it closer to initiating human trials for its gene therapies targeting age-related diseases.
Genflow Biosciences Advances SIRT6 Variant Patent Application Following Positive Search Report from European Patent Office
Genflow Biosciences PLC (LSE: GENF), a leading company in the field of longevity, has revealed plans to reorganize its primary board of directors and scientific advisory board (SAB) in order
Genflow (LSE: GENF) is pleased to announce it has entered into a research agreement with Magnitude Biosciences Limited (“Magnitude”), a UK-based, specialist biotechnology research organisation that supports drug discovery and
Patent portfolio strengthened with international patent application under the Patent Cooperation Treaty